This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original articles
van der Heijden, M. S. et al. Nivolumab plus gemcitabine–cisplatin in advanced urothelial carcinoma. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2309863 (2023)
McGregor, B. A. et al. The Double Antibody Drug conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma. Ann. Oncol. https://doi.org/10.1016/j.annonc.2023.09.3114 (2023)
Fakih, M. G. et al. Sotorasib plus panitumumab in refractory colorectal cancer with mutated KRAS G12C. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2308795 (2023)
Hassel, J. C. et al. Three-year overall survival with tebentafusp in metastatic uveal melanoma. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2304753 (2023)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Killock, D. From the ESMO Congress 2023. Nat Rev Clin Oncol 21, 3 (2024). https://doi.org/10.1038/s41571-023-00835-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-023-00835-1